<clinical_study>
<study_id>
<org_name>
  Boehringer
</org_name>
<org_full_name>
  Boehringer Ingelheim Pharmaceuticals
</org_full_name>
<org_study_id>
  248.538
</org_study_id>
<secondary_id>
  Eudract No 2007-000073-39
</secondary_id>
<nct_id>
  NCT00144300
</nct_id>
</study_id>
<brief_title>
<textblock>
Efficacy, Safety, Tolerability of   Pramipexol ER Versus Pramipexol IR  Versus  Placebo in  Early  Parkinson Disease  (PD) Patients  
</textblock>
</brief_title>
<official_title>
<textblock>
  A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson&apos;s Disease Patients
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Boehringer Ingelheim Pharmaceuticals
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Boehringer Ingelheim, Study Chair
</name_title>
<organization>
  Boehringer Ingelheim
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  The objectives of this trial conducted in early PD patients are to determine the efficacy       (as measured by the change from baseline to the end of the maintenance phase in the total score for UPDRS Parts II and III combined), safety, and tolerability of Pramipexole ER      (in daily doses from 0.375mg to 4.5mg q.d.) in comparison to placebo, and to test for non-inferiority between the two formulations (ER and IR) of pramipexole. 
  In addition, the efficacy of Pramipexole IR will be compared to placebo, for assay sensitivity
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Recruiting
</status>
<date>
2008-10 
</date>
</status_block>
<start_date>
<date>
  2005-01
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<primary_compl_date
 type="Anticipated"
>
<date>
  2010-07
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 4
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
Treatment 
</design>
<design>
  Parallel Assignment
</design>
<design>
Safety/Efficacy Study  
</design>
<primary_outcome>
<measure>
 The primary efficacy endpoint of the trial is     the   change from baseline to end of    the maintenance period in          UPDRS parts II+III score. 
</measure>
<time_frame>
33 weeks 
</time_frame>
</primary_outcome>
<secondary_outcome>
<measure>
  Responder rate for Clinical Global Impression of Improvement 
  Responder rate for Patient Global Impression of Improvement 
  UPDRS I, II and III scores separately
</measure>
<time_frame>
33 weeks 
</time_frame>
</secondary_outcome>
<enrollment
 type="Anticipated"
>
  300
</enrollment>
<condition>
  Parkinson Disease
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  pramipexole IR
</primary_name>
<description>
<textblock>
</textblock>
</description>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  ropinirole
</primary_name>
<description>
<textblock>
</textblock>
</description>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
  1.	Male or female patient with idiopathic Parkinsons disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.
  2.	Parkinsons disease diagnosed within 5 years. 
  3.	Patients 30 years of age or older at the time of diagnosis.
  4.	Modified Hoehn and Yahr stage of 1 to 3.
  5.	Patients requiring additional therapy/ introduction of therapy (for de novo patients) to treat their parkinsonian symptoms at the time of enrolment (screening visit, V1) according to the investigators judgement. 
 
 
  Exclusion Criteria:
  1.	Atypical parkinsonian syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic disorders (e.g., Wilson&apos;s disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy).
  2.	Dementia, as defined by a Mini-Mental State Exam score &lt; 24 at screening visit   
  3.	Any psychiatric disorder according to DSM-IV
  4.	History of psychosis
  5.	Clinically significant electrocardiogram (ECG) abnormalities at screening visit 
  6.	Clinically significant hypotension 
  7.	Malignant melanoma or history of previously treated malignant melanoma
  8.	Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study
  9.	Pregnancy
  10.	Sexually active female of childbearing potential not using a medically approved method of birth control 
  11.	Serum levels of AST (SGOT), ALT (SGPT), alkaline phosphatases or bilirubin &gt; 2 ULN  
  12.	Patients with a creatinine clearance &lt; 50 mL/min 
  13.	Any dopamine agonist (including pramipexole) within 4 weeks prior to baseline visit, or L-Dopa within 8 weeks prior to baseline visit.
  14.	Total cumulative duration of prior exposure to Levodopa of more than 3 months.
  15.	Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit
  16.	Any of the following drugs within 4 weeks prior to the baseline visit: methylphenidate, cinnarizine, amphetamines.
  17.	Flunarizine within 3 months prior to baseline visit
  18.	Known hypersensitivity to Pramipexole or its excipients
  19.	Drug abuse (including alcohol), according to Investigators judgement, within 2 years prior to screening.
  20.	Participation in other investigational drug studies or use of other investigational drugs within one month or five times the half-life of the investigational drug
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  30 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Chair
</role>
<name>
  Boehringer Ingelheim
</name>
<affiliation>
<agency>
  Boehringer Ingelheim
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Boehringer Ingelheim Study Coordinator
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
clintriage.rdg@boehringer-ingelheim.com 
</email>
</contact>
<location>
<facility>
<name>
248.538.00007 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Birmingham
</city>
<state>
  Alabama
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00008 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Little Rock
</city>
<state>
  Arkansas
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00021 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Fountain Valley
</city>
<state>
  California
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00022 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Los Angeles
</city>
<state>
  California
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00001 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  New Haven
</city>
<state>
  Connecticut
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00002 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Miami
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00016 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Tampa
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00023 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Tampa
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00009 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Augusta
</city>
<state>
  Georgia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00013 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Atlanta
</city>
<state>
  Georgia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00011 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Chicago
</city>
<state>
  Illinois
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00005 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Baltimore
</city>
<state>
  Maryland
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00014 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Southfield
</city>
<state>
  Michigan
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00010 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00015 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00020 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00012 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Charlotte
</city>
<state>
  North Carolina
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00006 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Philadelphia
</city>
<state>
  Pennsylvania
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00004 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Memphis
</city>
<state>
  Tennessee
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00003 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Houston
</city>
<state>
  Texas
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<location>
<facility>
<name>
248.538.00017 Boehringer  Ingelheim  Investigational  Site  
</name>
<address>
<city>
  Morgantown
</city>
<state>
  West Virginia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
</location>
<initial_release_date>
  2005-09-02
</initial_release_date>
<last_release_date>
2008-10-01 
</last_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
